Australia-based Zelira Therapeutics Ltd. ZLDAF, a company developing cannabinoid-based medicines, announced that it is entering the German market via a 5-year exclusive distribution agreement with IM Cannabis Corp. IMCC IMCC.
Distribution will be done by IM Cannabis’ subsidiary, German-based Adjupharm, a EU GMP-certified medical cannabis distributor.
The distribution agreement expands the availability of Zenivol, Zelira’s clinically validated cannabinoid-based insomnia medication, beyond Australia and into Germany.
In the first half of 2020, over €75 million worth of medical cannabis products were sold in Germany to an estimated patient population of around 120,000, according to the company.
The companies will seek reimbursement for its sales of Zenivol from the German government.
The agreement follows the publication of research results from a University of Western Australia's double-blind, placebo-controlled, cross-over trial of Zenivol in chronic insomnia patients in the peer-reviewed journal Sleep.
Photo by Ketut Subiyanto from Pexels.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!